Gastroprotective Agents for Naproxen Use

Introduction to Gastroprotection

The American Gastroenterological Association recommends using a standard-dose proton pump inhibitor (PPI) such as omeprazole 20 mg once daily as the gastroprotective agent of choice when prescribing naproxen for 4 weeks 1, 2, 3, 4

PPIs are the most effective gastroprotective strategy for preventing both gastric and duodenal ulcers in patients taking NSAIDs like naproxen, with standard doses significantly reducing gastric and duodenal ulcers associated with NSAID use in numerous clinical trials 1, 2, 3
The American College of Gastroenterology states that PPIs provide superior protection compared to H2-receptor antagonists (H2-RAs), which reduce only duodenal ulcers but not gastric ulcers in NSAID users 1, 2, 3, 4

In a study of high-risk patients with recent complicated peptic ulcers using naproxen, omeprazole was much more effective than H. pylori eradication alone in preventing ulcer bleeding recurrence after 6 months 2, 3
Misoprostol 200 mcg three to four times daily reduces gastric ulcer risk by 74% and duodenal ulcer risk by 53% compared to placebo, although its use is limited by adverse effects including diarrhea, nausea, and abdominal pain 2, 3, 4

High-risk features for NSAID-induced upper GI complications include history of peptic ulcer or ulcer complications, concomitant use of aspirin, anticoagulants, or corticosteroids, and multiple risk factors present 3, 4, 5, 6, 7
For high-risk patients on naproxen, the American Heart Association suggests using PPI co-therapy at standard doses (omeprazole 20-40 mg daily) and considering switching to a COX-2 selective inhibitor plus PPI for maximum protection if cardiovascular risk permits 2, 3, 4

The American Gastroenterological Association recommends testing and treating H. pylori if present in patients with prior ulcer history before starting naproxen, although H. pylori eradication alone is not sufficient to prevent upper GI damage in patients with previous ulcer history who need NSAIDs—additional PPI co-therapy must be added 2, 3, 4, 5

Poor compliance with gastroprotective therapy increases the relative risk of NSAID-induced upper GI adverse events 4-6 times, with over one-third of patients prescribed gastroprotective therapy being partially or non-adherent 1, 2, 3

The FDA-approved dosing for omeprazole supports use up to 4-8 weeks for various indications, making this duration appropriate and safe for a 4-week naproxen course, although long-term PPI use carries very low rates of side effects 1, 2, 3